Foghorn Therapeutics Inc.(FHTX)Earnings, Financials & Key RatiosFoghorn Therapeutics Inc. (FHTX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on external funding is underscored by a narrowing cash position of $88.9 million against a consistent quarterly burn rate that threatens long-term solvency.
Foghorn Therapeutics Inc. (FHTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Foghorn Therapeutics Inc. (FHTX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.29vs $0.28-3.6% | $3Mvs $8M-58.9% |
| Q2 2026 | Mar 11, 2026 | $0.34vs $0.28-21.4% | $9Mvs $10M-8.9% |
| Q4 2025 | Nov 5, 2025 | $0.25vs $0.31+19.4% | $8Mvs $9M-14.2% |
| Q3 2025 | Aug 5, 2025 | $0.28vs $0.31+9.7% | $8Mvs $8M-7.5% |
Recent stock market news and headlines for Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncology His appointment will strengthen Step Pharma's board as it advances dencatistat across three clinical programmes for essential thrombocythaemia (ET), lymphoma and solid tumours.
Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Neil J. Gallagher, MD, PhD, as Non-Executive Director effective immediately. He will support the Company as it continues to advance its first-in-class CTPS1 inhibitor, dencatistat, as a treatment for essential thrombocythaemia, lymphoma and solid tumours.
Key metrics vs top competitors for Foghorn Therapeutics Inc. (FHTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.00 | $352.28M | -5.08 | 36.75% | -240.33% | — | — | |
| $190.46 | $40.49B | -32.01 | — | — | -83.22% | — | |
| $30.12 | $3.5B | -34.62 | 48.29% | -188.15% | -41.54% | — | |
| $0.67 | $28.65M | -1.08 | 13.77% | -4726.21% | -69.57% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $16.22 | $2.09B | 7.84 | 20.38% | 99.97% | 64.48% | — |
Foghorn Therapeutics Inc. (FHTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Foghorn Therapeutics Inc. (FHTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Apr 21, 2026·SEC
Mar 11, 2026·SEC
Get notified when FHTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Foghorn Therapeutics Inc. (FHTX) stock FAQ — growth, dividends, profitability & financials explained
Foghorn Therapeutics Inc. (FHTX) reported $28.2M in revenue for fiscal year 2025.
Foghorn Therapeutics Inc. (FHTX) grew revenue by 36.8% over the past year. This is strong growth.
Foghorn Therapeutics Inc. (FHTX) reported a net loss of $75.3M for fiscal year 2025.
Foghorn Therapeutics Inc. (FHTX) had negative free cash flow of $87.4M in fiscal year 2025, likely due to heavy capital investments.
